Titan Pharma rises as co starts strategic alternatives review

Titan Pharmaceuticals

21/12/2021 13:54

** Titan Pharmaceuticals Inc shares up 7.5% at $1.15
premarket after co announces it's exploring strategic
alternatives
    ** Specialty pharma firm says commenced process to enhance
shareholder value, including an acquisition, merger, reverse
merger, other business combination  urn:newsml:reuters.com:*:nPn9XKs5da
    ** Maxim Group serving as financial advisor to assist in
process
    ** In Oct, co said it received funding from the Bill &
Melinda Gates Foundation to develop combination HIV preventative
therapeutic and contraceptive implant for women in low- and
middle-income countries, without disclosing the funding amount
 urn:newsml:reuters.com:*:nL4N2RL2V1
    ** TTNP has fallen 67% this year, following ~44% drop in
2020
    

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-332-219-1430))